GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dianthus Therapeutics Inc (NAS:DNTH) » Definitions » Notes Receivable

DNTH (Dianthus Therapeutics) Notes Receivable : $0.00 Mil (As of Mar. 2025)


View and export this data going back to 2023. Start your Free Trial

What is Dianthus Therapeutics Notes Receivable?

Dianthus Therapeutics's Notes Receivable for the quarter that ended in Mar. 2025 was $0.00 Mil.


Dianthus Therapeutics Notes Receivable Historical Data

The historical data trend for Dianthus Therapeutics's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dianthus Therapeutics Notes Receivable Chart

Dianthus Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Notes Receivable
- - - -

Dianthus Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Dianthus Therapeutics Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Dianthus Therapeutics Notes Receivable Related Terms

Thank you for viewing the detailed overview of Dianthus Therapeutics's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Dianthus Therapeutics Business Description

Traded in Other Exchanges
Address
7 Times Square, 43rd Floor, New York, NY, USA, 10036
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.